Ep 35 – Saturday at TLMdX 2020 from AASLD: Lean NASH, exciting Diagnostics and Patient-Reported Outcomes as an Endpoint

Manal Abdelmalek joins the Surfers to review some of Saturday's most exciting presentations and posters from AASLD 2020, followed by a discussion of an exciting new hand-held diagnostic

This Episode Is Sponsored By

 


Manal Abdelmalek joins the Surfers in a free-flowing discussion of Saturday’s key papers and posters. Much of the talk focused on Lean NASH — what it is some of the new diagnostic analyses and algorithms used to identify patients with or at risk of the disease.

Stephen talked about the extraordinary path that seladelpar took through its Phase 2 NASH trial and Roger revisited an old podcast question: can Patient-Reported Outcomes be part of clinical development planning and, if so, for what kinds of drugs.

Finally, the Surfers welcomed Dr. Nezam Afdhal of Harvard and George Aliphteras of Sonic Incytes in a sponsored extra-sode that is part of the rollout of Velacur, their handheld liver health assessment device. The discussion moved quickly and at the end, all the Surfers were struck powerfully by how dynamically we are learning about this disease.

Roger Green — 1662
ASSESSMENT OF PATIENT-REPORTED OUTCOMES IN A LARGE COHORT OF NASH PATIENTS WITHOUT CIRRHOSIS — ZOBAIR YOUNOSSI

Donna Cryer —  0060
CLINICIAL CHARACTERISTICS USED FOR MACHINE LEARNING IDENTIFICATION OF FAST PROGRESSORS AMONG PATIENTS WITH NASH — JOERN SCHATTENBERG.

Louise Campbell MSc AP — 0056 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL — JEROME BOURSIER

Dr. Stephen Harrison — 1710 A 52-WEEK MULTI-CENTER DOUBLE-BLIND RANDOMIZED PHASE 2 STUDY OF SELADELPAR, A POTENT AND SELECTIVE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA (PPAR-DELTA) AGONIST, IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)

Manal F. Abdelmalek — 0057
GEMS, A Genetic Metabolic Staging Predicting the Outcome of NAFLD — GRAZIA PENNISI

Sonic Incytes is on a mission to reduce chronic liver disease by enabling routine assessment and management of liver health. Its breakthrough, point of care ultrasound solution, Velacur™, assesses and manages chronic liver disease with diagnostic accuracy that is comparable to MRI. Learn more: www.sonicincytes.com

Similar Episode Categories

SUBSCRIBE

Subscribe for free. New podcasts Wednesday Evening / Thursday Morning.

Apple
Spotify
Google
Stitcher
Buzzsprout
YouTube
SoundCloud

ASK

We record each week and answer your questions along with our focussed topics. To have your question answered in future episodes… 

CONNECT

Join The Discussion in our LinkedIn or Facebook Discussion Groups

Sign Up For Email Notifications when the next episode is available!

We record each week and answer your questions along with our focussed topics. To have your question answered in the future episode, submit your question no later than Tuesday afternoon by 2pm. You can also Tweet @HEPdyamics

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Surfing NASH Tsunami

Advance Notification

We send out emails to notify our followers before we post on social media, and often it's before your podcast app is updated!